AASLD 2023 Practice Guidance on the Clinical Assessment and Management of MASLD/MASH
Three-setting clinical pathway linking primary care FIB-4 screening, secondary VCTE or ELF risk tiers, and GI/hepatology specialist staging.
Think of the AASLD pathway as a traffic map between your regular doctor and a liver specialist. A FIB-4 under 1.3 lets you stay safely with primary care and recheck in 1 to 3 years. A FIB-4 above 2.67 sends you straight to a liver specialist. If you land in the middle zone (1.3 to 2.67), a second test — FibroScan (VCTE) or the ELF blood score — sorts out whether your scarring is low, intermediate, or high risk.
Clinical Risk-Stratification Pathway Across Care Settings
- FIB-4 every 1–2 years if T2D/pre-T2D or ≥2 metabolic risk factors
- FIB-4 every 2–3 years if no T2D and <2 metabolic risk factors
Note: If persistent ↑ALT and AST → Consider referral to GI/Hepatology.
- Cardiometabolic risk reduction and preferential use of medicines with potential MASLD benefit
- Ongoing assessment of alcohol intake
- Lifestyle management
Perform VCTE™ (kPa) or ELF™ score:
| Risk Level | VCTE™ (kPa) | or ELF™ |
|---|---|---|
| Low | <8.0 | <7.7 |
| Intermediate | 8–12 | 7.7–9.8 |
| High | >12 | >9.8 |
- Review/perform primary/secondary risk assessment
- Consider additional stratification with MRE, cT1
- Indeterminate NITs
- Diagnostic uncertainty
- Persistently ↑ALT and AST
Suspected cirrhosis (clinical, imaging, or ELF™ >11.3) → Proceed directly to Stage 4 / Cirrhosis-based management